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The specific aim of this study targets to reduce the rejection in post lung transplant
subjects by increasing the amount of CCL21 by injecting the DC/CCL21 vaccination
to express T and B cells more efficiently.4
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Figure 1. Comparison of a normal/healthy lung versus a degraded lung with IPF.3
Figure 3. Comparison of the different types of infection post transplant in 3 different areas of
the body. 1
• DC/CCL21 inhibits CCL21 to decrease the number of deaths world-wide post-
lung transplant
• Overtime, there would be higher survival rates
• More data to help prevent chronic rejection in lung transplant recipients
• Possible leads to curing particular uncured lung diseases like IPF to one day
lowering the number of patients on the transplant list
Figure 2. CCL21 expression is improved in mice post-DC/CCL21 vaccination.
Immunofluorescence staining of LNs and spleen was performed on day 50 after transplant to
assess for CCL21 (blue), B cells (B220) (green) and T cells (CD8a)(red).5
• Chemokines are a part of the innate and adaptive immune system which can
help fight inflammation in the body.6
• CCL21 is expressed in the lymph nodes to help guide naïve T cells and can be
beneficial when treating patients with transplant rejection, as well as, help
with immunologic tolerance.2
• TNF- α is part of the signaling pathway to bring in other proteins to fight
infections/inflammation.4
• IL-4 is secreted during an anti-inflammatory response to help activate B cells
and control T cell proliferation.6
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